Implanted pump improves chemotherapy survival rates
This article was originally published in Clinica
Executive Summary
Patients with implanted chemotherapy pumps show significantly increased survival rates over those receiving traditional chemotherapy after surgery for metastatic liver cancer, according to two US studies. As a result, the pump should be used as the standard treatment for liver metastases from colorectal cancer, Dr Elin Sigurdson of Fox Chase Cancer Center told oncologists this week at the Society of Surgical Oncology's annual cancer symposium in New Orleans, Louisiana.